Scholar Rock (SRRK): A New Frontier in Treating Spinal Muscular Atrophy

What happens when treating the underlying genetic cause of a disease is only part of the solution?

Scholar Rock (SRRK) is helping answer that question.

In September 2026, the FDA approved ISEMBYLD (apitegromab-mstn), the first muscle-targeted therapy for spinal muscular atrophy (SMA).

SMA is a genetic neuromuscular disease that leads to progressive muscle weakness. Existing disease-modifying treatments target the underlying SMN protein deficiency. ISEMBYLD takes a complementary approach by inhibiting myostatin, a protein that regulates muscle growth.

Why is this different?

For years, advances in SMA treatment have focused on addressing the underlying deficiency of survival motor neuron (SMN) protein. These therapies have fundamentally changed the treatment landscape by helping preserve motor neurons.

However, even patients receiving these therapies can continue to experience significant muscle weakness and functional limitations.

Scholar Rock is approaching the problem from a different direction.

Its therapy inhibits the activation of myostatin, a naturally occurring protein that limits skeletal muscle growth. Rather than replacing existing SMN-directed therapies, ISEMBYLD is designed to complement them by directly targeting muscle.

The Hammersmith Functional Motor Scale–Expanded (HFMSE) measures physical abilities such as sitting, rolling and other motor tasks. The primary efficacy population included 103 children aged 2–12, within a broader trial of 188 participants aged 2–21.

The clinical results are encouraging.

In the pivotal Phase 3 SAPPHIRE trial, patients receiving the recommended ISEMBYLD dose alongside an SMN2-targeted therapy demonstrated a statistically significant 2.2-point improvement in motor function relative to placebo after one year.

Importantly, 34.2% of patients receiving ISEMBYLD achieved at least a three-point improvement on a standardized motor-function scale, compared with 13.5% of patients receiving placebo.

For individuals living with a progressive neuromuscular disease, preserving or improving physical capabilities represents an important therapeutic objective.

Now comes the commercial challenge.

Scholar Rock began its U.S. launch following FDA approval on September 11, 2026, with initial patients receiving treatment in October.

The company is also pursuing regulatory approvals in Europe and Japan and evaluating additional opportunities for its myostatin-targeting technology.

The investment story is transitioning from demonstrating clinical efficacy to establishing patient access, physician adoption and sustainable commercial demand.

Why this matters for healthcare investors

Scholar Rock illustrates a broader evolution in biotechnology.

The next generation of treatments may increasingly combine therapies that address the biological origins of disease with therapies designed to improve the resulting functional impairments.

This creates opportunities for innovative medicines to complement existing standards of care rather than simply replace them.

The commercial story: Approval is the beginning

$0.6M

Q3 2026 ISEMBYLD revenue

$413.6M

Cash and marketable securities, Sept. 30

$205M

Agreed priority review voucher sale

Source: Scholar Rock Q3 results, November 10, 2026. The voucher sale was subject to closing conditions; proceeds should not yet be treated as received cash.

SEC+1